Genprex, Inc. operates as a clinical-stage gene therapy company. The company engages in developing technologies for cancer patients based upon a proprietary technology platform. Its platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. The company's lead product candidate, Oncoprex immunogene therapy for non-small cell lung cancer (NSCLC), has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex also block mechanisms that create drug resistance. The company was founded in 2009 and is headquartered in Austin, Texas.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [01/22/2020 10:10 PST] Genprex, Inc. (NASDAQ:GNPX), Up By 100.00% ($1.31) From $1.310 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [01/22/2020 07:50 PST] GNPX Expected to Trade Up Short Term
• [01/13/2020 10:10 PST] Genprex, Inc. (NASDAQ:GNPX), Up By 100.00% ($0.35) From $0.353 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [01/09/2020 07:36 PST] GNPX Expected to Trade Up After Bullish Patterns Develop
• [01/03/2020 10:48 PST] Genprex, Inc. (NASDAQ:GNPX), Down By 100.00% ($0.31) From $0.310 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [01/03/2020 07:57 PST] GNPX Expected to Trade Down After Bearish Patterns Develop